Latest News and Press Releases
Want to stay updated on the latest news?
-
TORONTO, July 17, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and...
-
TORONTO, June 28, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and...
-
Avicanna’s proprietary SEDDS technology capsules are designed for enhanced and rapid absorption of cannabinoids. Avicanna and Medipharm intend to commercialize various formulations of Avicanna’s...
-
TORONTO, June 22, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on...
-
This Research Collaboration will be led by Dr. Jessica Kalra’s research team and focus on characterization of Avicanna’s proprietary products and drug pipeline formulations This Research...
-
TORONTO, May 29, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and...
-
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
-
TORONTO, May 16, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing,...
-
MyMedi.ca to provide Medical Cannabis by Shoppers patients a complete medical cannabis care platform including curated products and services. NGC will facilitate inventory management and fulfillment...
-
92% Y-Y increase in Canadian product sales, driven by increased number of commercial SKUs and listings. $4M in revenue, representing 24% Y-Y growth coupled with reduction in SG&A and 35% in EBITA...